Insights | Vantage Biomedical Partners

Featured

Market Analysis

The 2025 Medical Device M&A Landscape: What VCs Need to Know

After a sluggish 2024, medical device M&A is showing signs of recovery. We analyze the key trends, valuation multiples, and strategic priorities that will shape deal flow in the coming year—and what it means for your portfolio companies.

January 8, 2025 12 min read

Read Article

Regulatory

Jan 6, 2025 8 min

FDA's New 510(k) Guidance: 5 Critical Changes for 2025

The FDA's updated 510(k) guidance introduces significant changes to predicate device selection and clinical data requirements. Here's what founders and investors need to understand.

Due Diligence

Jan 3, 2025 6 min

The Predicate Trap: Why 510(k) Strategy Kills More Deals Than You Think

We've seen it too many times: a promising device company builds their entire regulatory strategy on a predicate that was never appropriate.

Market Analysis

Dec 28, 2024 10 min

AI in Medical Devices: Separating Hype from Investment-Grade Innovation

Every pitch deck now features "AI-powered" somewhere. But which AI medical device plays are actually defensible? We break down the regulatory realities.

Case Insight

Dec 20, 2024 5 min

Anatomy of a Failed Device Launch: Lessons from a $40M Write-Off

An anonymized deep-dive into how a well-funded surgical device company missed every adoption signal. The warning signs were there at Series A.

Regulatory

Dec 15, 2024 7 min

EU MDR Update: What the Latest Extensions Mean for US Companies

The EU MDR timeline continues to shift. We analyze the latest guidance and what it means for US device companies planning European market entry.

Due Diligence

Dec 10, 2024 9 min

Reimbursement Red Flags: The Questions VCs Forget to Ask

Clinical efficacy means nothing if payers won't cover it. We outline the reimbursement diligence framework that separates fundable opportunities.

Medical Device Intelligence

The 2025 Medical Device M&A Landscape: What VCs Need to Know

FDA's New 510(k) Guidance: 5 Critical Changes for 2025

The Predicate Trap: Why 510(k) Strategy Kills More Deals Than You Think

AI in Medical Devices: Separating Hype from Investment-Grade Innovation

Anatomy of a Failed Device Launch: Lessons from a $40M Write-Off

EU MDR Update: What the Latest Extensions Mean for US Companies

Reimbursement Red Flags: The Questions VCs Forget to Ask

Need Custom Analysis?

Medical Device Intelligence

The 2025 Medical Device M&A Landscape: What VCs Need to Know

FDA's New 510(k) Guidance: 5 Critical Changes for 2025

The Predicate Trap: Why 510(k) Strategy Kills More Deals Than You Think

AI in Medical Devices: Separating Hype from Investment-Grade Innovation

Anatomy of a Failed Device Launch: Lessons from a $40M Write-Off

EU MDR Update: What the Latest Extensions Mean for US Companies

Reimbursement Red Flags: The Questions VCs Forget to Ask

Get Insights Delivered

Need Custom Analysis?